- Bashir, Mustafa R;
- Wolfson, Tanya;
- Gamst, Anthony C;
- Fowler, Kathryn J;
- Ohliger, Michael;
- Shah, Shetal N;
- Alazraki, Adina;
- Trout, Andrew T;
- Behling, Cynthia;
- Allende, Daniela S;
- Loomba, Rohit;
- Sanyal, Arun;
- Schwimmer, Jeffrey;
- Lavine, Joel E;
- Shen, Wei;
- Tonascia, James;
- Van Natta, Mark L;
- Mamidipalli, Adrija;
- Hooker, Jonathan;
- Kowdley, Kris V;
- Middleton, Michael S;
- Sirlin, Claude B;
- Network, on behalf of the NASH Clinical Research
Background
The liver R2* value is widely used as a measure of liver iron but may be confounded by the presence of hepatic steatosis and other covariates.Purpose
To identify the most influential covariates for liver R2* values in patients with nonalcoholic fatty liver disease (NAFLD).Study type
Retrospective analysis of prospectively acquired data.Population
Baseline data from 204 subjects enrolled in NAFLD/NASH (nonalcoholic steatohepatitis) treatment trials.Field strength
1.5T and 3T; chemical-shift encoded multiecho gradient echo.Assessment
Correlation between liver proton density fat fraction and R2*; assessment for demographic, metabolic, laboratory, MRI-derived, and histological covariates of liver R2*.Statistical tests
Pearson's and Spearman's correlations; univariate analysis; gradient boosting machines (GBM) multivariable machine-learning method.Results
Hepatic proton density fat fraction (PDFF) was the most strongly correlated covariate for R2* at both 1.5T (r = 0.652, P < 0.0001) and at 3T (r = 0.586, P < 0.0001). In the GBM analysis, hepatic PDFF was the most influential covariate for hepatic R2*, with relative influences (RIs) of 61.3% at 1.5T and 47.5% at 3T; less influential covariates had RIs of up to 11.5% at 1.5T and 16.7% at 3T. Nonhepatocellular iron was weakly associated with R2* at 3T only (RI 6.7%), and hepatocellular iron was not associated with R2* at either field strength.Data conclusion
Hepatic PDFF is the most influential covariate for R2* at both 1.5T and 3T; nonhepatocellular iron deposition is weakly associated with liver R2* at 3T only.Level of evidence
4 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:1456-1466.